Oragenics Inc OGEN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OGEN is a good fit for your portfolio.
News
-
Oragenics, Inc. Files 10K and Provides Company Update
-
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
-
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
-
Oragenics Announces Closing of Public Offering
-
Oragenics Announces Pricing of Public Offering
-
Oragenics Announces Proposed Public Offering
-
Oragenics, Inc. Announces Leadership Transition
-
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
Trading Information
- Previous Close Price
- $1.08
- Day Range
- $1.11–1.16
- 52-Week Range
- $1.02–7.74
- Bid/Ask
- $1.10 / $1.20
- Market Cap
- $5.06 Mil
- Volume/Avg
- 23,459 / 104,005
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.oragenics.com
Valuation
|
Metric
|
OGEN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.21 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OGEN
|
|---|---|
Quick Ratio | 1.94 |
Current Ratio | 2.15 |
Interest Coverage | −681.10 |
Quick Ratio
OGEN
Profitability
|
Metric
|
OGEN
|
|---|---|
Return on Assets (Normalized) | −203.34% |
Return on Equity (Normalized) | −304.36% |
Return on Invested Capital (Normalized) | −233.84% |
Return on Assets
OGEN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fglhkbkft | Ftts | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wlvqszd | Grtdth | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Bjfwzqxd | Wzkygg | $98.1 Bil | |
MRNA
| Moderna Inc | Xxxrwxyj | Rknj | $39.1 Bil | |
ARGX
| argenx SE ADR | Hjmrdbpmk | Dlkz | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Xynxgbpqh | Mks | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ypjylywdm | Bjjbhk | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kmpprjbt | Vpvthr | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dfhwmgmmx | Wvfjdk | $12.5 Bil | |
INCY
| Incyte Corp | Jkbhjlh | Qndpjyg | $11.9 Bil |